ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow dips below year-ago levels
Q1 FY2026 free cash flow of $41.89M (cash outflow) fell 38.4% year over year, behind the +12.4% change in trailing-twelve-month free cash flow. Sequentially, it rose 36.6% from the prior quarter. Over 3 fiscal years it compounded at +54.4% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -38.4% toward the trailing-twelve-month pace of +12.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (160.59M) USD
- Year-over-year change
- -128.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (160.59M) | -128.7% |
| FY2024 | 2024-12-31 | (70.21M) | -25.7% |
| FY2023 | 2023-12-31 | (55.84M) | -28.0% |
| FY2022 | 2022-12-31 | (43.63M) | -246.6% |
| FY2021 | 2021-12-31 | (12.59M) | — |
Free Cash Flow vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 free cash flow of $134.47M is the 3rd largest of the 11 companies compared; the peer median is $85.33M.
- Its year-over-year change of +12.4% is the 4th highest of 11, against a peer median of -14.2%.
- Over three fiscal years its annual growth of +54.4% compares with a peer median of +3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $1.16B | +60.2% | +55.6% | 47.5% | |
| LTM Jun 2026 | $162.52M | -28.5% | -25.2% | 36.1% | |
| LTM Mar 2026 | $134.47M | +12.4% | +54.4% | — | |
| LTM Mar 2026 | $111.36M | -4.5% | +13.9% | — | |
| LTM Sep 2026 | $109.24M | +11.0% | -7.3% | — | |
| LTM Mar 2026 | $102.47M | +38.9% | +23.3% | — | |
| LTM Mar 2026 | $87.93M | -67.2% | -6.8% | 39.0% | |
| LTM Jun 2026 | $82.72M | -50.9% | +21.7% | 48.7% | |
| LTM Mar 2026 | $53.6M | +72.0% | — | 23.6% | |
| LTM Jun 2025 | $49.66M | -24.0% | -36.3% | 8.2% | |
| LTM Mar 2026 | $34.03M | -225.9% | — | — | |
| Peer median (excluding AVBP) | $85.33M | -14.2% | +3.6% | 37.6% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | (3.03M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 66.67K | 424K | 895K | 3.21M | 12.52M |
| Change in Working Capital | (3.94M) | (7.15M) | 12.6M | 7.07M | (3.77M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 293K | 2.8M | 1.38M | (751K) | 2.14M |
| Other Working Capital | (4.23M) | (9.95M) | 11.22M | 7.82M | (5.92M) |
| Other Non-Cash Items | 42.96M | 0 | 0 | 0 | 0 |
| Operating Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (25M) | (194.16M) | (272.93M) |
| Sales of Investments | 0 | 0 | 25M | 1.7M | 201.71M |
| Other Investing Activities | (40M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (40M) | 0 | 0 | (192.47M) | (71.23M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.87M | 2K | 354K | 185.95M | 202.63M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 15K | (2.06M) | 631K | (70K) |
| Financing Cash Flow | 89.87M | 169.72M | 42.86M | 186.58M | 203.06M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.28M | 126.09M | (12.98M) | (76.1M) | (28.75M) |
| Free Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.